Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.

Recurrence after hepatic resection in colorectal cancer liver metastasis -Review article-. J Med Life (2015) 0.79

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83

Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg (1999) 14.31

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol (2003) 12.82

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst (2004) 10.61

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2008) 9.98

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol (2009) 5.57

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet (2011) 5.29

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol (2004) 4.78

Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg (1996) 4.41

Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95

Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery (1990) 3.93

Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg (2000) 2.92

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol (1999) 2.80

Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg (1989) 2.79

Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol (2005) 2.66

Liver resection for colorectal metastases: the third hepatectomy. Ann Surg (2003) 2.57

Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol (2009) 2.26

Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg (1997) 2.18

Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg (2008) 2.10

Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg (2006) 1.76

Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg (1986) 1.72

Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64

Hepatectomy for liver metastases. Br J Surg (1993) 1.50

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. Br J Cancer (2009) 1.48

Changes in hepatic lobe volume in biliary tract cancer patients after right portal vein embolization. Hepatology (1995) 1.43

Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol (2005) 1.41

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol (2010) 1.36

Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol (2000) 1.31

Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J Gastrointest Surg (2007) 1.25

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25

Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol (1992) 1.13

Role of surgery in colorectal cancer liver metastases. World J Gastroenterol (2014) 1.13

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol (2012) 1.08

Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol (2008) 1.01

Neo-adjuvant therapy improves resectability rates for colorectal liver metastases. Ann R Coll Surg Engl (2001) 1.00

Ligation of a branch of the portal vein for carcinoma of the liver. Am J Surg (1975) 0.98

Perioperative chemotherapy and liver resection for hepatic metastases of colorectal cancer. J Hepatobiliary Pancreat Sci (2012) 0.81